Growing Diabetes Pandemic Worldwide

Slides:



Advertisements
Similar presentations
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Advertisements

Benefits of intensive multiple risk factor intervention.
UKPDS Paper 36 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Glycemic Control: When the Lower is Not the “Better”?
Prevalence (%) estimates of diabetes (20-79 years) 2010.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Disclosure Consultations and Honoraria Grant Support
Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.
Copyright © 2007 American Medical Association. All rights reserved.
Diabetes and Risk of CV Outcomes
CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?
New Insights on PPAR Agonists For Cardiovascular Disease
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
What Comes Second?.
SGLT2 Inhibitors in Phase 3 Trials
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Examining CV Effects of Basal Insulin Therapy
Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.
Early Type 2 Diabetes Mellitus: A Cardiovascular Disease
Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.
Impacting CV Risk With Diabetes Medications
Blood pressure control: dependence on adherence
Impacting CV Risk With Diabetes Medications
Clinical Application of New CV Outcomes Data
T2DM and CV Outcomes Trials: A Deep Dive!
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Statins and Glucose Metabolism: Are All Agents Alike?
UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes
Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.
A Journal Club on Lipid Management:
Tackling CV Risk in T2DM.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
LEADER One Year On.
Learning Objectives Metabolic Abnormalities Associated With T2D.
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Antihyperglycemic Therapy
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Updates in Cardiovascular Medicine
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pharmacotherapy for Diabetic Coronary Disease:
Need for better diabetes treatment for improved renal outcome
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Statins and Glucose Metabolism: An Endocrinology Perspective
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Emerging Advances in Reducing Renal Complications of T2D
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
Presentation transcript:

Growing Diabetes Pandemic Worldwide

Approved Antidiabetic Medications

Cardiovascular Benefits to Tighter HbA1c Control?

UKPDS 10-Year Follow-Up

Effects of More- vs Less-Intensive Glycemic Control

Sulfonylureas and CV Mortality

Summary of RCT and Meta-Analysis Data on Thiazolidinediones and Myocardial Infarction Risk

Incretin-based Drugs

DPP4i Cardiovascular Meta-Analysis

EXAMINE

SAVOR-TIMI 53 Summary

SAVOR-TIMI 53 Summary

SGLT2 Inhibition: Novel Mechanism

ADVANCE Trial: Systolic Blood Pressure at the End of Follow-Up Period

ACCORD BP

Benefits of Statins in Diabetes

STENO-2: Multifactorial Approach To Improve CV Outcomes in T2D

Mean Changes in Weight, Fitness, and Cardiovascular Disease Risk Factors in Intensive Lifestyle Intervention (ILI) and Diabetes Support and Education (DES) Groups and the Difference Between Groups Averaged Across 4 Years

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.